GlassScriptPhysician profile
Marisha Sirdar
NPI 1770016966
$1,875.02
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2021: $196 · 2022: $819 · 2023: $304 · 2024: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $451.23 | 2021-2024 | Ozempic, Wegovy |
| Abbvie INC. | $191.70 | 2021-2024 | Ubrelvy |
| Glaxosmithkline, LLC. | $142.98 | 2022-2024 | Trelegy Ellipta |
| Intuity Medical INC | $142.40 | 2022 | |
| Genentech USA, INC. | $136.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $119.83 | 2021 | |
| Pfizer INC. | $93.63 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.87 | 2022-2023 | |
| Exact Sciences Corporation | $79.77 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $61.63 | 2022-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $47.33 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $38.86 | 2021-2024 | Farxiga |
| Mannkind Corporation | $35.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.38 | 2022-2024 | Jardiance |
| Lilly USA, LLC | $34.53 | 2022-2024 | Zepbound, Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27.61 | 2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $19.43 | 2021 | |
| Merck Sharp & Dohme LLC | $19.34 | 2022 | |
| Vanda Pharmaceuticals INC. | $19.25 | 2022 | |
| Medtronic, INC. | $18.47 | 2024 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $16.51 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $15.91 | 2022 | |
| Boston Scientific Corporation | $15.17 | 2023 | Watchman Access System |
| Supernus Pharmaceuticals, INC. | $12.86 | 2023 | Qelbree |
| Dynavax Technologies Corporation | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisha Sirdar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.